The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction

Cancer

Volumn 80, Issue 6, 1997, Pages 1034-1045

  Ishida, Hironori ^a   Irie, Koji ^b   Itoh, Tsuyoshi ^a   Furukawa, Tsugio ^b   Tokunaga, Osamu ^a  

^a SAGA UNIVERSITY   (Japan)

^b Saga Prefectural Hospital   (Japan)

Author keywords

bcl 2; Ki 67; Lung adenocarcinoma; p53; Poliferative activity; Survival analysis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; DNA, COMPLEMENTARY; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030761399     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970915)80:6<1034::AID-CNCR5>3.0.CO;2-9     Document Type: Article

References (51)

1. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.
2. Tsugane S, Watanabe S, Sugimura H, Urano Y, Matsubara S. Recent trends in different histological types of lung cancer in Tokyo based on pathological autopsy records. Jpn J Cancer Res 1987;78:162-9.
3. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96: 440-7.
4. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993; 103:449S-56S.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
6. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
7. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
9. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
10. Greenblatt MS, Bennet WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
11. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, et al. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 1995;4:93-7.
12. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-31.
13. Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, et al. Prognostic significance of p53 and ras p-21 expression in nonsmall cell lung cancer. Cancer 1995;76: 2457-63.
14. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992;66:735-8.
15. Brambilla E, Gazzeri S, Moro D, Caron de Fromentel C, Gouyer V, Jacrot M, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993;143: 199-210.
16. Tsujimoto Y, Yunis J, Onorato SL, Erikson J, Nowell PC, Croce CM. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984;224: 1403-6.
17. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990;137:225-32.
18. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
19. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. Bcl-2 protein in non-small-cell lung carcinoma. New Engl J Med 1993;329:690-4.
20. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995;71:1003-7.
21. Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
22. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
23. Hurlimann J, Larrinaga B, Vala DL. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995;426: 163-8.
24. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch 1995;426:229-33.
25. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994; 172:337-42.
26. Henriksen R, Wilander E, Öberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-9.
27. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
28. Bubendorf L, Sauter G, Moch H, Jordan P, Blöchlinger A, Gasser TC, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-65.
29. Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 1995; 121:357-63.
30. Baretton GB, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenoma and carcinomas. Cancer 1996;77:255-64.
31. Pezzella F, Mprrison H, Jones M, Gatter KC, Lane D, Harris AL, et al. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993; 22:39-44.
32. Beahrs OH, Hensin DE, Hutter RVP, Kennedy BJ. Lung. In: Manual for staging of cancer. 4th edition. Chicago: American Joint Committee on Cancer, 1992;115-22.
33. World Health Organization. Histological typing of lung tumors, No.1. 2nd edition. Geneva: World Health Organization, 1981.
34. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994;106(Suppl 6):377S-81S.
35. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee J, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995;13:1893-903.
36. Shohat O, Greenberg M, Reisman D, Oren M, Rotter V. Inhibition of cell growth mediated by plasmids encoding p53 antisense. Oncogene 1987;1:277-85.
37. Tungekar MF, Gatter KC, Dunnill MS, Mason DY. Ki-67 immunostaining and survival in operable lung cancer. Histopathology 1991; 19:545-50.
38. Scagliotti GV, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P, et al. Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer 1993;29A: 363-5.
39. Pence JC, Kerns BJ, Dodge RK, Iglehart JD. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 1993;128; 1382-90.
40. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.
41. Harpole DH Jr., Herndon JE II, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55: 51-6.
42. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 1994;54:3714-7.
43. Nakamura S, Akazawa K, Kinukawa N, Yao T, Tsuneyoshi M. Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Hum Pathol 1996;27:225-33.
44. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
45. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
46. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-7.
47. Guinee DG Jr., Travis WD, Trivers GE, De Benedetti VMG, Cawley H, Welsh JA, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and c-erb B-2 expression. Carcinogenesis 1995;16: 993-1002.
48. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, et al. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 1995;6:S9-S13.
49. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-5.
50. Hartmann A, Blaszyk H, MacGovern RM, Schroeder JJ, Cunningham J, De Vries EMG, et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogens 1995; 10:681-8.
51. Lane DP. p53: guardian of the genome. Nature 1992;358:15-6.